السبت , 20 أكتوبر 2018
عاجل
الرئيسية / سياسة / [:en] Last patient randomized in Zogenix’s late-stage study of ZX008 in Dravet [:]
[:en] Last patient randomized in Zogenix’s late-stage study of ZX008 in Dravet [:]
Трейдер на фондовой бирже в Нью-Йорке. 12 мая 2015 года. Фондовые рынки США завершили торги вторника разнонаправленно, а индекс S&P 500 незначительно поднялся после трехдневного падения благодаря акциям финансовых компаний и производителей потребительских товаров. REUTERS/Brendan McDermid

[:en] Last patient randomized in Zogenix’s late-stage study of ZX008 in Dravet [:]

1003 عدد الزيارات
[:en]
  • Zogenix (NASDAQ:ZGNX) reports that the last subject has been randomized in its Phase 3 clinical trial, Study 1, assessing lead product candidate, Fast Track-tagged ZX008, for the treatment of Dravet syndrome. The estimated completion date is September 1.
  • The company is also conducting another Phase 3, Study 1504, where participants are receiving standard-of-care treatment of stiripentol, valproate and clobazam as baseline. According to ClinicalTrials.gov, the estimated study completion date is August.
  • ZX008 is a low-dose fenfluramine. It was the “Fen” component of the anti-obesity medication Fen-phen that was withdrawn from the U.S. market in 1997 due to its association with heart valve disease. It has Orphan Drug status in the U.S. for Lennox-Gastaut syndrome and Fast Track status for Dravet syndrome.
  • Now read: Heron Therapeutics: Giving A ‘Thumbs Up’ To This ~$14 Biopharma Stock
[:]
شارك الخبر علي صفحات التواصل الإجتماعي
ads motabeq

عن رئيس التحرير